Colitis

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis.

ABSTRACT Patients were less tolerant of CBD-rich botanical extract compared with placebo, taking on average one-third fewer capsules, and having more compliance-related protocol deviations (principally insufficient exposure), prompting identification of a per protocol (PP) analysis set. The primary endpoint was negative; end of treatment remission rates were similar for CBD-rich botanical extract (28%) and placebo …

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. Read More »

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

ABSTRACT Experimental evidence gathered from preclinical IBD models and conducted in rodents point to a strong potential of the ECS components to serve as drug targets in inflammatory diseases of the intestine. Data suggest a homeostatic role of the ECS in the gut. Accordingly, it is believed that the enhancement of endocannabinoid signaling, as observed …

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Read More »

Cannabinoids as novel anti-inflammatory drugs

ABSTRACT Cannabinoids have been shown to regulate the tissue response to excessive inflammation in the colon, mediated by both dampening smooth-muscular irritation caused by inflammation and suppressing proinflammatory cytokines, thus controlling the cellular pathways leading to inflammatory responses. These results strongly suggest that modulation of the physiological activity of the cannabinoid system during colonic inflammation …

Cannabinoids as novel anti-inflammatory drugs Read More »

Scroll to Top
{"cart_token":"","hash":"","cart_data":""}